Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
$0.88
-5.3%
$1.00
$0.66
$17.75
$5.29M0.23795,334 shs47,046 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$13.43
-1.2%
$13.14
$1.10
$15.85
$21.57M1.252,160 shs1,877 shs
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$2.50
+4.3%
$2.43
$1.87
$4.20
$20.68M120,522 shs14,923 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.44
+0.6%
$3.15
$2.57
$6.88
$21.13M0.639,025 shs3,426 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-5.26%-11.10%-23.47%-16.18%-46.34%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-1.24%-1.96%-0.36%-1.96%+949.38%
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
+4.33%+1.79%-4.79%+9.82%-24.12%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.56%+0.56%+3.90%-4.87%-44.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.3545 of 5 stars
0.04.00.00.00.60.00.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.391 of 5 stars
0.03.00.00.00.01.70.6
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
2.4128 of 5 stars
3.53.00.00.01.80.01.3
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6152 of 5 stars
0.03.00.00.01.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
0.00
N/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
3.00
Buy$15.00499.04% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATNF, FNCH, LSTA, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/8/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
3/22/2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/A$2.91 per shareN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$110K196.11N/AN/A$14.25 per share0.94
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
$1M21.58N/AN/A$3.49 per share0.72
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
-$6.17MN/A0.00N/AN/A-147.32%-76.99%8/11/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A

Latest ATNF, FNCH, LSTA, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A-$0.67N/A-$0.67N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/8/2025Q1 2025
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
-$0.53-$0.55-$0.02-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
N/A
1.02
1.02
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
N/A
7.52
7.52
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNF
180 Life Sciences
75.70 million5.69 millionNo Data
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Lisata Therapeutics, Inc. stock logo
LSTA
Lisata Therapeutics
308.62 million7.79 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

(NAII) Trading Advice
(NAII) Pivots Trading Plans and Risk Controls

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNF

$0.88 -0.05 (-5.26%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$0.91 +0.03 (+3.51%)
As of 06/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$13.43 -0.17 (-1.24%)
As of 06/18/2025 11:52 AM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Lisata Therapeutics stock logo

Lisata Therapeutics NASDAQ:LSTA

$2.52 +0.13 (+5.21%)
As of 06/18/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.44 +0.02 (+0.56%)
Closing price 06/18/2025 03:58 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 06/18/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.